The final program will focus on scientific perspectives, research and development and various forms of birth tissue clinical application.
- Outline scientific perspectives in cellular viability and bioactivity.
- Summarize clarifications and perspectives in homologous use.
- Review ongoing research and development initiatives.
- Summarize common clinical applications.
Dr. Namin is the Vice President of Research and Development for UMTB Biomedical, Inc. She is responsible for leading product development of all cell and tissue-based products for the company. In addition, Dr. Namin is an important member of the commercialization team. Her main interest is the development of regenerative therapies focused around amniotic derived tissue products. As such, Dr. Namin has played an integral role in developing and commercializing the company’s amniotic tissue offerings. Dr. Namin received her bachelors and Ph.D. in Biomedical Engineering from Florida International University. She also received an MBA and MS in Industrial Engineering from the University of Miami. During her studies, Dr. Namin spent several years working in many different facets of the tissue engineering realm, with a focus on the commercialization of cell and tissue-based products. She has multiple publications and patents for her work on the development of these therapies. She is currently an active member of the Scientific & Technical Affairs Committee (STAC) for the American Association of Tissue Banks.
Processing and Clinical Application
Speaker: Shabnam M. Namin, Ph.D., MBA, CTBS
Day: November 28, 2018
Time: 2:00 p.m. - 3:00 p.m. EST